Genitourinary/Renal

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
AGS-16C3F-15-3A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell CarcinomaHotte, Dr Sebastien OpenNCT02639182
MK-3475-426A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)Hotte, Dr Sebastien OpenNCT02853331
KEYNOTE 427A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Advanced Renal Cell Carcinoma (MK-3475-427)Hotte, Dr Sebastien OpenNCT02853344
CO39303 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WITH PTEN-LOSS (PTEN DIAGNOSTIC POSITIVE) TUMORSMukherjee, Dr SomOpenNCT03072238
PROfoundA Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have
Homologous Recombination Repair Gene Mutations (PROfound)
Hotte, Dr Sebastien OpenNCT02987543
WO39210A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED RENAL CELL CARCINOMA AT INTERMEDIATE TO HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMYHotte, Dr Sebastien OpenNCT03024996
IND.223A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpenNCT02905318
IND.232A Phase II Study of Durvalumab With or Without Tremelimumab in Patients With Metastatic castration Resistant Prostate CancerHotte, Dr Sebastien OpenNCT02788773
OCOG-2013-PETMUSEImpact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder StagingMukherjee, Dr SomOpenNCT02462239
OCOG-2016-MISTERAssessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel PET Radiotracers in Castration-Resistant Prostate CancerHotte, Dr Sebastien OpenNCT02813226
OZM-053A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Renal Cell Cancer Patients Receiving 1st Line Sunitinib TherapySwaminath, Dr AnandOpenNCT02019576
OZM-054A Phase II, randomized, multi-center study of cabazitaxel versus abiraterone or enzalutamide in poor prognosis-metastatic castration-resistant prostate cancerHotte, Dr Sebastien OpenNCT02254785
The PACE StudyPACE - International Randomized Study of Laparoscopic Prostatectomy vs Robotic Radiosurgery and Conventionally Fractionated Radiotherapy vs Radiosurgery for Early Stage Organ-Confined Prostate CancerDayes, Dr IanOpenNCT01584258
TOPCOPTOward Personalizing Care for Older men with mCRPC - understanding and predicting treatment toxicities (the TOPCOP study)Hotte, Dr Sebastien OpenNCT02512185
TRITON2A Multicenter, Open-label Phase 2 Study of Rucaparib in
Patients with Metastatic Castration-resistant Prostate Cancer Associated
with Homologous Recombination Deficiency
Hotte, Dr Sebastien OpenNCT02952534
WO30070A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, PARTIAL -BLIND STUDY OF ATEZOLIZUMAB (ANTI-PDL1 ANTIBODY) MONOTHERAPY AND IN COMBINATION WITH PLATIMUN BASED THERAPY VERSUS PLATINUM BASED THERAPY PLUS PLACEBO IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMAMukherjee, Dr SomOpenNCT02807636
Download PDF